We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pfizer Japan announced April 12 that it has received approval to manufacture
VFEND, its proprietary antifungul agent, from the Ministry of Health, Labor
and Welfare.VFEND, which has a broad antifungul spectrum, is proven effective
against Aspergillus, a type of fungus.
Xsira Pharmaceuticals announced that it has in-licensed worldwide rights to
develop adenosine as an analgesic for the reduction of postoperative pain following
surgery.
Cystic Fibrosis Foundation Therapeutics, the drug discovery and development
affiliate of the Cystic Fibrosis Foundation, and Galapagos, a genomics-based
drug discovery company, have initiated a two-year target discovery alliance.
Dutch biotechnology company Crucell N.V. announced that it has signed a manufacturing
contract with the Vaccine Research Center (VRC), part of the National Institute
of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health
(NIH), for the manufacture of vaccines against Ebola infections.
Sawai Pharmaceutical, a Japanese pharmaceutical specialized in manufacturing
generic products, announced on April 13 that it has basically agreed with Nihon
Schering on an upcoming business transfer.
Connetics, a specialty pharmaceutical company focused on dermatology, announced
it has signed an agreement with Ventiv Commercial Services Group (VCS), a division
of Ventiv Health, whereby VCS will provide sales support for certain Connetics
products to primary care physicians (PCP) and pediatricians.
Spectrum Pharmaceuticals announced that it has entered
into an exclusive agreement with Cura Pharmaceuticals Co., Inc. for the marketing
and distribution of carboplatin injection.
Echoing recent criticism of the FDA's oversight of drug products, a new British
parliamentary report cites "significant failings" in the ability of
UK health officials to regulate the domestic pharmaceutical industry.
Israel's new data exclusivity provision for pharmaceutical products, which provides
market protection for novel drugs, has drawn the ire of U.S. brand trade group
PhRMA, which contends the measure has a loophole that could cut exclusivity
periods even shorter than proposed.